• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Loss of China Rights for Jing Zhu Da Might Change The Case For Investing In Syndax (SNDX)

    Simply Wall St·08/17/2026 14:20:43
    Listen to the news
    • In August 2026, Edding Genor Group disclosed that Syndax Pharmaceuticals had terminated its 2013 license with EOC Pharma, immediately ending all sublicenses for Jing Zhu Da and halting related commercialization arrangements in Mainland China.
    • This termination not only suspends Eddingpharm’s planned cancer product rollout and linked commission streams, but also raises questions about how Syndax intends to handle access and partnerships for this asset in one of the world’s largest oncology markets.
    • We’ll now examine how the loss of Jing Zhu Da commercialization rights in China could reshape Syndax’s existing growth-focused investment narrative.

    The future of work is here. Discover the 37 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

    Syndax Pharmaceuticals Investment Narrative Recap

    To own Syndax, you need to believe its value still rests on Revuforj and Niktimvo, with near term performance and label progress driving the story. The sudden loss of Jing Zhu Da commercialization rights in China looks more like a setback in optionality than a hit to the core US focused catalyst path, but it underlines how partnership and geographic execution risks can surface quickly.

    The most relevant recent update here is Syndax’s second quarter 2026 earnings, where revenue reached US$72.79 million and net loss narrowed to US$49.36 million. Those numbers highlight how much the current thesis depends on continued uptake of Revuforj and Niktimvo in approved indications, which is where investors are watching for confirmation of the growth narrative while keeping one eye on ongoing cash burn and expense levels.

    Yet beneath the promising revenue ramp, the concentration in just two main drugs and the fresh China licensing break are exactly the kind of risk investors should be aware of...

    Read the full narrative on Syndax Pharmaceuticals (it's free!)

    Syndax Pharmaceuticals' narrative projects $748.0 million revenue and $110.2 million earnings by 2029. This requires 63.1% yearly revenue growth and a $395.6 million earnings increase from -$285.4 million today.

    Uncover how Syndax Pharmaceuticals' forecasts yield a $39.50 fair value, a 99% upside to its current price.

    Exploring Other Perspectives

    SNDX 1-Year Stock Price Chart
    SNDX 1-Year Stock Price Chart

    Before this licensing surprise, the most optimistic analysts were expecting revenues near US$942.1 million and earnings of about US$182.7 million by 2029, but this China setback shows how dependence on just two core assets can cut both ways and why your view on upside versus execution risk may now need a fresh look.

    Explore 5 other fair value estimates on Syndax Pharmaceuticals - why the stock might be worth just $19.52!

    Reach Your Own Conclusion

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    • A great starting point for your Syndax Pharmaceuticals research is our analysis highlighting 2 key rewards that could impact your investment decision.
    • Our free Syndax Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Syndax Pharmaceuticals' overall financial health at a glance.

    Ready To Venture Into Other Investment Styles?

    Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.